Topical skin-care active with early cosmetic signals for fine lines, hydration, texture, and redness. Human data are small, short-term, and mostly developer-affiliated. Risks look low (mainly local irritation). Optional add-on, not proven aging or disease treatment. (Full Review)

Protocol

Form / strength

Leave-on gel or serum ~1–3%

1% wrinkle/hydration package; 3% rosacea pilot

Frequency

Once or twice daily

Clean, dry skin; start once daily if multi-active

Time of day

Morning and/or evening

Morning under sunscreen; evening with barrier repair

Time to effect

Fine lines / wrinkles

~12 weeks

1% gel vehicle-controlled cosmetic package

Hydration / appearance

~12 weeks

Same 1% clinical timeframe

Redness / lesions

~4 weeks

3% open-label rosacea pilot

Benefits

Medium: Improved appearance of fine lines and wrinkles; improved skin hydration and barrier-related feel

Low: Reduced facial erythema and inflammatory lesions; smoother texture, brightness, and overall appearance

Speculative: Matrix protection via lower collagenase and oxidative stress

Contraindications

Known allergy to farnesylcysteine derivatives or any formula excipient

Broken, infected, or post-procedure skin until re-epithelialized (unless clinician-directed)

Pregnancy and lactation (absence of dedicated safety data, not proven harm)

Children (no pediatric cosmetic efficacy/safety package identified)

Key Interactions

Prescription topicals (retinoids such as tretinoin, tazarotene)

Leave-on acids (glycolic, salicylic, lactic) and strong vitamin C serums

Oral photosensitizing drugs (e.g., doxycycline, some isotretinoin courses)

Other anti-inflammatory topicals (azelaic acid, metronidazole, ivermectin for rosacea)

Supplements with skin-barrier roles (oral ceramides, omega-3 fatty acids)

Risk & Side Effects

Low: Local irritation, stinging, or redness

Speculative: Delayed contact allergy or ingredient-specific sensitization; systemic exposure or off-target effects with extensive use

Monitoring

Marker	Target	Why
Clinical photos (standardized)	Improvement vs personal baseline	Tracks lines, texture, redness
Subjective stinging/redness score (0–10)	Stable or lower vs baseline	Detects irritation early
Corneometry (if available)	Rise vs personal baseline	Objective hydration trend
Transepidermal water loss (if available)	Stable or lower vs baseline	Barrier integrity
Systemic blood panel	Not established for SFC	No validated SFC biomarkers

Cadence: Photos/clinical check at ~4 weeks and 8–12 weeks; stinging score daily first 2 weeks, then weekly

Qualitative Assessment

Smoother makeup application or less “tight” skin feel
Less reactive redness after mild triggers (temperature, exercise) if that was a baseline complaint
No progressive dryness, scale, or itch attributable to the new product

Disodium Succinoyl Farnesylcysteine for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment